Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Roche Holding AG
  6. News
  7. Summary
    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Press Release : New four-year data show Roche's -2-

10/14/2021 | 01:03am EST

Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. In recent years, Roche has invested in genomic profiling and real-world data partnerships and has become an industry-leading partner for medical insights.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the twelfth consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2020 employed more than 100,000 people worldwide. In 2020, Roche invested CHF 12.2 billion in R&D and posted sales of CHF 58.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

*Relapse associated with low likelihood of recovery, resulting in permanent disability

Roche Group Media Relations

Phone: +41 61 688 8888 / e-mail: media.relations@roche.com https://www.globenewswire.com/Tracker?data=PQ18mNy5E8aRfAAj5YOqTKMHx2PMwRg_F8QwFN0RfAcTDMcchw8SsBLbOvfYAYDOsabbAdoto86wT4ixCq837lvUThMCtu2wjWPeEv5JLjHscAfXhAiwUZMl-lstlral

 
Dr. Nicolas Dunant          Patrick Barth 
 Phone: +41 61 687 05 17     Phone: +41 61 688 44 86 
Dr. Barbara von Schnurbein  Karsten Kleine 
 Phone: +41 61 687 89 67     Phone: +41 61 682 28 31 
Nina Mählitz           Nathalie Meetz 
 Phone: +41 79 327 54 74     Phone: +41 61 687 43 05 
 Sileia Urech 
 Phone: +41 79 935 81 48 
 
 
Roche Investor Relations 
Dr. Karl Mahler                               Jon Kaspar Bayard 
 Phone: +41 61 68-78503                        Phone: +41 61 68-83894 
 e-mail: mailto:karl.mahler@roche.com          e-mail: jon_kaspar.bayard@roche.com 
 karl.mahler@roche.com 
--------------------------------------------  -------------------------------------- 
Dr. Sabine Borngräber                    Dr. Bruno Eschli 
 Phone: +41 61 68-88027                        Phone: +41 61 68-75284 
 e-mail: mailto:sabine.borngraeber@roche.com   e-mail: bruno.eschli@roche.com 
 sabine.borngraeber@roche.com 
--------------------------------------------  -------------------------------------- 
Dr. Birgit Masjost                            Dr. Gerard Tobin 
 Phone: +41 61 68-84814                        Phone: +41 61 68-72942 
 e-mail: mailto:birgit.masjost@roche.com       e-mail: mailto:gerard.tobin@roche.com 
 birgit.masjost@roche.com                      gerard.tobin@roche.com 
--------------------------------------------  -------------------------------------- 
 
Investor Relations North America 
Loren Kalm 
 Phone: +1 650 225 3217 
 e-mail: mailto:kalm.loren@gene.com 
 kalm.loren@gene.com 
-------------------------------------------- 
 

Attachment

   -- 14102021_MR_Enspryng_SAkuraStar and SAkuraSky_en 
      https://ml-eu.globenewswire.com/Resource/Download/93a693ac-8012-46fb-8dfa-af5c69d5d5d5 
 
 
 

(END) Dow Jones Newswires

October 14, 2021 01:03 ET (05:03 GMT)

All news about ROCHE HOLDING AG
09:57aJazz Pharmaceuticals Announces First Patient Enrolled in IMforte Phase 3 Trial Evaluati..
AQ
06:38aAlphaValue/Baader Europe Lowers Price Target on Roche, Maintains Add Recommendation
MT
01:17aRoche Closes Biotechnology Group TIB Molbiol Acquisition
MT
01:01aRoche completes purchase agreement with long-term partner TIB Molbiol to expand PCR-tes..
AQ
11/30Roche Uses Amazon Web Services For Most Cloud Needs
MT
11/29Thermo Fisher says its COVID-19 tests accurately detects Omicron variant
RE
11/26Chugai Pharmaceutical Co. - Anti Cancer Agent Herceptin Approved for Additional Indicat..
AQ
11/26Roche Shareholders Approve Deal to Buy Back Novartis' Stake in Swiss Drugmaker
MT
11/26Roche shareholders approve deal to buy Novartis's $20.7 billion stake
RE
11/26Roche Shareholders OK $21 Billion Repurchase Deal With Novartis
MT
More news
Analyst Recommendations on ROCHE HOLDING AG
More recommendations
Financials
Sales 2021 62 134 M 67 601 M 67 601 M
Net income 2021 15 273 M 16 617 M 16 617 M
Net cash 2021 4 368 M 4 752 M 4 752 M
P/E ratio 2021 19,6x
Yield 2021 2,59%
Capitalization 316 B 343 B 344 B
EV / Sales 2021 5,01x
EV / Sales 2022 4,90x
Nbr of Employees 101 465
Free-Float 83,5%
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 359,65 CHF
Average target price 388,44 CHF
Spread / Average Target 8,01%
EPS Revisions
Managers and Directors
Severin Schwan Chief Executive Officer & Executive Director
Alan Hippe Chief Financial & Information Technology Officer
Christoph Franz Chairman
Urs Jaisli Chief Compliance Officer
AndrÚ S. Hoffmann Vice Chairman
Sector and Competitors
1st jan.Capi. (M$)
ROCHE HOLDING AG16.39%337 091
JOHNSON & JOHNSON-0.92%410 501
PFIZER, INC.45.97%301 579
NOVO NORDISK A/S65.17%243 741
ELI LILLY AND COMPANY46.91%224 871
ABBVIE INC.7.59%203 801